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Abstract
Current medicine, highly technified, and capable of amazing achievements, is not possible 
without the support of antibiotics. The problem of antibiotic resistance is almost as old as 
the antibiotics themselves. But at present, it is a serious threat to public health. We have to 
fight against antibiotic resistance in the hospital and in the out-of-hospital environment. 
The Resistance Zero program, promoted by the Spanish Society of Intensive Medicine, 
has achieved through a multidisciplinary approach with collaboration between doctors, 
nurses, cleaning staff and microbiologists, to control the colonization and infection by 
multiresistant germs in the environment of the Intensive Care Unit.




The emergence of antibiotic and their use in clinical practice is one of the greatest achievements 
of Medicine. In the mid-twentieth century, its use became widespread, and it was thought that 
a rapid and definite eradication of infectious diseases was possible. However, the first resistant 
bacteria soon appeared, and antibiotic resistance has developed into a serious public health 
problem. It is estimated that up to 60% of nosocomial infections are caused by resistant germs 
both in Europe and in the United States. The Center for Disease Control and prevention (CDC) 
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in the United States has estimated that the problem of antibiotic resistance is responsible for 2 
million infections and 23,000 deaths per year with a direct cost of 20 billion dollars, and losses of 
productivity equivalent to 33 billion dollars [1]; the European Center for Disease Control, ECDC, 
have estimated that accounts for 25,000 deaths and 1.5 billion € per year by infections by multire-
sistant bacteria (MRB) [2]. Some consequences of this problem are: increased cost of health care, 
increased rates of failure of antibiotic treatment and increased mortality. This is not a problem 
limited to certain regions or countries and resistance can spread quickly in our globalized world.
1.2. Intensive care unit generalities
Intensive care unit (ICU) accounts for less than 10% of total beds in most hospitals, but more 
than 20% of nosocomial infections are acquired in ICU [3]. Acquired in ICU infections pose 
significant morbidity, mortality and expense; they are the most frequent cause of death in 
non-cardiac ICUs and 40% of all ICU expenses [4]. In comparison with patients from other 
areas of the hospital, ICU patients have higher chronic comorbidity, more severe acute physi-
ological deterioration and are relatively immunosuppressed [5]. Its management also implies 
a high degree of invasiveness, with use of intravascular catheter, contact with a large number 
of health personnel—predisposing to colonization and infection—and are subjected to an 
increased colonization pressure [5].
When a patient goes to the hospital today, he undergoes a more effective and complete care 
than in previous years. Advances in diagnostic and therapeutic methods mean improvements 
in care and may be accompanied by a greater number of associated complications. All these 
data are magnified in ICU; ICU patients are more vulnerable to develop infections during 
their stay and to become colonized/infected with MRB. Overcrowding in closed areas of these 
severely ill patients with multiple comorbidities and subjected to invasive devices are risk 
factors for the development of nosocomial infections.
There is a clear relationship between the appearance of resistance and the highest antibiotic 
consumption. Infections due to resistant germs/MRB have limited therapeutic options, so 
inadequate empirical treatments are prescribed, the start of the correct treatment is delayed 
and therapeutic failures increase. All this leads to longer ICU stay, costs and mortality, with 
worse prognosis of the patient.
The highest density of MRB is observed in ICU. The importance of adequate and early treat-
ment is greater in critically ill patients; for all above, it is necessary to implement programs 
for the prevention and treatment of multiresistant bacteria MRB, both in the ICU and in the 
community—a great number of MRB can be related to inadequate or excessively prolonged 
treatments in the general ward or outside the hospital.
1.3. Antibiotic resistance mechanisms
The mechanisms related to the emergence of resistance are varied. Resistance can be intrinsic 
or acquired. the first occurs in certain germs that are not innately sensitive to certain antibiot-
ics, by a special membrane structure or related to the mechanism of the antibiotic. There may 
be at the molecular level: modifications in the targets (nucleic acid, ribosomes, action points 
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of certain antibiotics—such as penicillin-binding proteins, PBPs); alterations in the transmem-
brane passage (porins, mechanisms of uptake or active transport); enzyme production (beta-
lactamases). The appearance of mutations in the genetic material of the bacteria or the transfer 
of resistance genes from other germs explains the transformation from sensible to resistant 
bacteria. The exposure to antibiotics induces the disappearance of a population sensitive, and 
the selection of resistant strains to the antibiotics that end up being predominant.
1.4. Definition of MRB
MRB are defined as those microorganisms resistant to three or more antibiotics, which must 
also have clinical relevance. The exception to this rule is methicillin-resistant Staphylococcus 
aureus (MRSA) and vancomycin-resistant enterococcus (VRE) cases, in which the resistance 
condition is given by only one antibiotic. The phenomenon of resistance constitutes a medical 
problem, since it becomes a difficulty for the treatment and also epidemiological relevance, 
given the possibility of transmission of the outbreak. The ESKAPE (Enterococcus faecium, 
Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa and Enterobacter especies) 
are a specific group of bacteria with clinical relevance, associated with health care, and with 
the capacity to develop antibiotic resistance [6].
1.5. Description of the MRB
P. aeruginosa (Pa) has a predilection for humid environments and usually contaminates aque-
ous solutions such as disinfectants or soaps, mechanical ventilation equipment, fiberoptic 
bronchoscopes, and so on. Resistance may appear in the course of an antibiotic treatment. Its 
main mechanism of resistance is the presence of extended-spectrum beta-lactamases (ESBL) 
and alterations in permeability (porin mutations and expulsion pumps).
Acinetobacter baumannii (Ab) contaminates and endemically colonizes the hospital environ-
ment. It is capable of surviving and rapidly developing resistance to the main classes of anti-
biotics, more frequently in summer [7]. Some strains can survive to environmental drying 
form months, which facilitates transmission via contamination of fómites in the hospital. The 
health personnel is usually carrier of Gram-negative bacilli (GNB) (30%). Outbreaks have 
been described in relation to contaminated mechanical ventilation equipment and manual 
transmission. Infections have also been described in war wounds and in situations of natural 
disasters. Sixty-three percent of bacterial isolation from war wounds in Iraq and Afghanistan 
corresponded to this germ [8]. Infections tend to appear in patients with long stay in the ICU 
and health centers, dependent on mechanical ventilation, central catheter carriers, and with 
prior treatment with third-generation cephalosporins, fluorquinolones or carbapenemes. 
Although patients with Ab infection have high mortality, it is not clear whether mortality can 
be attributed to infection or to life-threatening conditions [9]. Several factors are associated 
with mortality: isolation in blood cultures, presence of signs of sepsis/septic shock, resistance 
to imipenem, longer stay in ICU, pneumonia and diabetes mellitus [10]. Cases of commu-
nity acquisition have been described in situations of chronic obstructive pulmonary disease 
(COPD), diabetes, alcoholism and cancer [11]. It has great capacity to acquire and accumulate 
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resistance genes from other GNB via plasmids/transposons, with low permeability for many 
antibiotics, constitutive ejection pumps, production of beta-lactamases and so on.
Klebsiella pneumoniae (Kp) contaminates the medical material although its main reservoir is the 
digestive tract and the hands of the health care personnel from where it can give rise to epi-
demic outbreaks. Its main mechanism of resistance is the production of beta-lactamases. The 
genes that encode them are transmitted by plasmids, which contribute to their rapid diffusion 
among other GNB.
MRSA shows resistance to methicillin by means of a protein encoded in the mecA gene and 
transported in the chromosomal cassette SCCmec. The frequent use of vancomycin has led to 
the emergence of strains with intermediate or complete resistance to vancomycin by acquisition 
of the gene through a plasmid. They currently constitute up to 50% of Staphylococcus infections.
1.6. Factors that predispose to infections by MRB
Certain elements as advanced age, functional dependence, cognitive deterioration and comor-
bidities, prolonged hospital stays, contact with personnel sanitary, intravascular catheters, 
bladder catheterization, previous antibiotic treatment, and so on, contribute to an increased 
selective pressure (leading to the emergence of MRB) and increased colonization pressure 
(through an ineffective environmental containment) [11].
1.7. Consequences of infection by MRB
The prognosis of MRB infections is not good, with an increase in hospital stay, mortality and 
economic costs [12]. These types of infections are usually resistant to empirical therapies, 
which implies a delay in starting the correct antibiotic treatment. Also derived from this, the 
use of second line treatment with lower bactericidal capacity and less favorable pharmody-
namic/pharmacokinetic profile contributes to a higher incidence of adverse events. At times, 
a greater virulence of these germs has been described.
1.8. Colonization and infection
The difference between these two terms lies in the simple presence (colonization) or clinical 
involvement (infection). The oropharynx is colonized early by hospital flora, especially GNB, 
in critically ill patients. The risk of colonization increases with hospital stay and severity. In 
the same way, the administration of antibiotics systemically increases the risk of acquiring the 
carrier state. Patients with APACHE II greater than 20 are usually carriers of abnormal flora 
such as GNB and MRSA. The passage from colonization to infective germs is defined by the 
rupture of the natural defense mechanisms (neutropenia, immunosuppression), the patho-
genicity of the germ itself, alteration of the intestinal flora by antibiotic therapy previously 
administered. Altered mechanisms of clearance of germs are suggested. A necessary factor 
for the development of the infection is the overgrowth; 20–40% of carrier patients develop an 
infection, so those carriers must be actively identified when we want to control an outbreak 
of infection by resistant flora.
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1.9. Exogenous-endogenous infections in the ICU
Infections can be classified according to origin and carrier status:
• Exogenous: nonpreceded by digestive colonization. The infective flora is endemic to the 
ICU. It constitutes 10–15% of the infections acquired in critical care.
• Endogenous: preceded by colonization of the digestive system by potentially pathogenic 
germs (PPG). It is endogenous primary if the patient already has them at the time of admis-
sion. It is usually precocious and represents 50% of registered infections. The endogenous 
secondary is caused by germs acquired in the ICU and colonizes the patient before causing the 
infection. They represent 35–40% of infections acquired in critical care.
The multimodal prevention of nosocomial pneumonia is based on these concepts. Primary 
endogenous pneumonias can be prevented with a short course of antibiotics such as cefotaxima 
that eliminates the colonizing germs of the oropharynx and upper respiratory tract of the carriers. 
Endogenous pneumonia is treated with the prevention of the carrier state with enteral antibiot-
ics (PPG will not be able to adhere the coated mucosa of antibiotics). Exogenous pneumonia is 
prevented with hygienic measures.
1.10. Mechanisms of appearance and extension of resistance
The main responsible for the emergence and extension of resistance are the indiscriminate use of 
antibiotics and the transmission of resistant microorganism between humans (or between human 
and environment). The antibiotics exert a selective ecological pressure on the bacteria, thus pro-
moting the appearance of resistance germs. Inadequate practices of prevention of the infection 
along with inadequate hygienic measures will favor the extension of the bacteria. The strategies 
to avoid these phenomena are aimed at a better use of antibiotics (reducing the selective pressure) 
and optimizing the infection control measures (reducing the colonization pressure) [13, 14].
Some measures aimed at a rational use of antibiotics are the following:
• Evaluation committees: formed by clinicians, pharmacists and microbiologists; pursue the 
effective and safe use of antimicrobials, evaluate and guide decision making; and imple-
ment educational programs to improve the use of antibiotics;
• implementation of clinical guidelines and protocols to promote the proper use of antibiotics;
• to use a form with pre-authorization for broad-spectrum antibiotics (non-specific restriction);
• preferred use of limited spectrum antibiotics (first-generation cephalosporin);
• personalized audit (mandatory consultation with infectious disease specialists to improve 
the appropriateness of antibiotic therapy and to reduce the use of broad spectrum 
antibiotics);
• to use predictive scores for MRB infections can be useful to minimize both the time to initi-
ate appropriate antibiotic treatment and the unnecessary use of broad spectrum antibiotics.
While some measures of patient-patient transmission control are:




• contact isolation measures (very important in case of MRSA, ERV and germs producers of 
ESBL), even grouping the colonized/infected patients (cohorting) and having staff exclu-
sively dedicated to the care of these infectious patients;
• the use of universal contact precautions is not clear in all patients admitted to ICU;
• cutaneous decolonization/daily bath with chlorhexidine to colonized/infected patients 
(despite the limitations of the current studies) [15];
• decolonization of the upper respiratory tract and gastrointestinal tract. Several options: 
oropharyngeal decontamination with antiseptics (chlorhexidine); selective oropharyngeal 
decontamination (with nonabsorbable antibiotics applied to the oropharynx); and selective 
digestive decontamination (with nonabsorbable antibiotics applied to the oropharynx with 
intravenous antibiotics);
• surveillance of early infections by MRB (for early identification of these germs, control of 
outbreaks—imited in time—and situations of endemic increase of isolation);
• to implement strategies of infection prevention in relation to invasive devices (reduce the 
use of central venous catheters, bladder catheters, orotracheal tubes, etc);
• to regulate and monitor the process of cleaning, disinfection and environmental sterilization.
1.11. Proper antibiotic treatment
The evolution of an infectious process depends on the characteristics of the initial focus, the 
hemodynamic parameters, host factors, the responsible pathogen, in vitro antibiotic suscep-
tibility tests and the precocity of the appropriate antibiotic treatment. The use of antibiotics 
is, at the same time, part of the problem and the solution when we talk about antibiotic resis-
tance. Unfortunately, the emergence of resistance is faster than the creation of new antibiotics 
by the pharmaceutical industry. In general, the solution involves a global reduction in the 
consumption of antibiotics, although it is necessary to implement control programs aimed at 
rationalizing their use.
A frequently forgotten fact is that the majority of antibiotic consumption is done at the extra-
hospital level (Primary Care and food industry) [16]; it is necessary to regulate its use. Up to 
50% of antibiotics prescribed at the hospital level are unnecessary, many of them are broad 
spectrum. The inadequate use of antibiotics increases the mortality of patients with severe 
sepsis, subjects them to unnecessary adverse effects and generates unjustified expenses. On 
the other hand, it is of vital importance to define the role of prophylactic antibiotic treatment 
and also differentiate the systemic inflammatory response syndrome of any cause from a real 
infectious process.
The loss of sensitivity to antibiotics is to be solved with several strategies: to speed up the 
development of new antimicrobials—the initiative “10 × 20” of the IDSA; 10 new antimicrobi-
ans available on 2020; to improve the mechanisms of infection control in health centers; and 
Current Topics in Intensive Care Medicine42
to optimize the use of current antibiotics with the intention of extending their useful life. An 
adequate administration of antibiotics should be based on the following principles:
• early start (associated with microbiological cultures);
• proper choice of antibiotic: based on local ecology and habitual patterns of resistance;
• suitable doses, based on pharmacokinetic and pharmacodynamics data, taking into account 
that in critical patients the increase in volume of distribution, cardiac output and glomeru-
lar filtration requires the administration of doses that could be above the usual doses (cur-
rently available antibiotics rarely cause serious adverse effects);
• evaluate the need to maintain the started treatment: to remove unnecessary antibiotics by 
culture results, and if possible, to narrow the spectrum (de-escalation);
• adequate duration of antimicrobial treatment (usually too long due to the absence of evidence 
of optimal duration and for fear of suspending it if the evolution of the patient is good).
Different strategies have been described and tested to avoid resistance to antibiotic. Rotation 
consists of restricting in an established way an antibiotic or a class of antibiotics during a cer-
tain period of time, to reintroduce it later; the aim is to reduce the selective pressure exerted 
on the microbial flora and to minimize the appearance of resistance to rotated antibiotics. 
Cycling is to prescribe antibiotics according to a pre-established a priori sequence. In sched-
uling, an antibiotic or antibiotic class is replaced by another antibiotic or class with a com-
parable antimicrobial spectrum; there is change to another antimicrobial without returning 
to the initial agent. In rotation, there is a circular pattern. The usefulness of these strategies 
is theoretical. Periodic modifications would limit the generation of resistances by avoiding 
prolonged exposures to the same antimicrobial agent; the restriction of an antibiotic can result 
in the compensatory potentiation of the use of other unrestrained agents, with a later increase 
of resistance to these second agents. Also, the elimination for the selective pressure by an 
antibiotic when withdrawing its use does not imply the eradication of the genetic material 
responsible of the resistance. Despite the theoretical benefits of these strategies, their results 
are contradictory, and none of them have showed real benefit so far [17].
1.12. Epidemiological surveillance: multimodal prevention program
Epidemiological surveillance consists of the systematic collection, analysis and interpretation 
of data about a problem related to public health. The implementation of multimodal preven-
tion programs must have the following elements: identification of problems, implementation 
plan, involvement of managers, record of compliance with objectives and, finally, the analysis 
of obstacles that may arise. An essential aspect of these programs is learning: the absence of 
adherence to the measures of the program due to lack of information or insufficient learning 
time should be avoided.
The antimicrobial stewardship programs bring together specialists in infectious diseases, 
clinical pharmacologists, clinical microbiologists, epidemiologists and other, sometimes also 
intensivists, all of them gathered for the purpose of an adequate prescription of antibiotics. 
But this is just one aspect of a complex problem like antibiotic resistance.
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The 12 steps described by the CDC to prevent antibiotic resistance are the following:
• prevention of the infection:
• vaccine administration;
• removal the catheters (as soon as possible);
• effective diagnosis and treatment of the infection:
• analyze the sensitivity of the germ and to adapt the treatment to the pathogen;
• discuss with experts;
• appropriate use of antimicrobials:
• antibiotic control;
• knowledge of local microbiological data;
• treat the infection, not the colonization or the contamination;
• know how to refuse vancomycin;
• stop antibiotic treatment if patient has healed (propose the reduction of antibiotic treat-
ment according to the clinical situation of the patient);
• prevention of the transmission:
• isolate the pathogen;
• break the chain of infection.
2. Resistance Zero (RZ) project
The Spanish Society of Intensive Care (SEMICYUC) has developed several projects with the aim 
of reducing infectious events (nosocomial infections): Bacteremia Zero (BZ) (catheter-related 
bacteremia) and Pneumonia Zero (NZ) (pneumonia associated with mechanical ventilation). 
After the implementation of these projects, a sustained decrease in the rate of such infections, 
and globally nosocomial infections has been achieved (Figure 1). It has been described that, 
surprisingly, the rate of pneumonia associated with mechanical ventilation began to decrease 
with the start of the BZ Project.
The last project carried out is Resistance Zero (RZ). Its objectives are:
• Primary: reduce by 20% the appearance of one or more MRBs of Nosocomial origin that are 
identified during their admission in ICU;
• Secondary: describe the MRB map in spanish ICUs, differentiating those identified at the 
time of admission to the ICU and those that appear after 48 h of stay; promote and reinforce 
the safety culture in them; and create a network of UCIs, through the autonomous com-
munities, that apply safe practices of demonstrated effectiveness.
The aim of the project is to minimize the three factors that influence the appearance of MRB 
in critical patients: the adequate prescription of antibiotics, the early detection of MRB and 
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the prevention of its spread/cross colonization, and the elimination of reservoirs. The MRBs 
in follow-up are: MRSA, VRE, Enterobacteria resistant to third generation cephalosporins, 
especially the ESBL producers, and those resistant to carbapenems, especially the carbapen-
emase producers; P. aeruginosa resistant to> = 3 families of antibiotics including: carbapenems, 
cephalosporins, piperaziline/tazobactam, fluoroquinolones, aminoglycosides, colistin; and 
Acinetobacter baumannii resistant to carbapenems.
The recommendations of the project are:
1. Identify in each ICU at least one intensivist physician responsible for the control of anti-
biotics, with experience in surveillance and infection control and in the management of 
antibiotics. Systematically evaluate the use of antibiotics in ICUs and advise physicians 
responsible for patients with the intention of assessing reasons for prescription (indica-
tion), assessing choice and correct administration (dose, interval, duration) and possibility 
of withdrawal or adjustment.
2. Administer antibiotics empirically active against MRB only in infections with systemic 
response (severe sepsis, septic shock (SS)), and high suspicion of being MRB based on 
present risk factors and local epidemiology. In other cases, it is recommended to use lower 
spectrum antibiotics and/or wait for microbiology results to start antibiotics directed to 
MRB (carbapenems, colistin, tigecycline, glycopeptides, daptomycin, linezolid). In critical 
surgical patients with infection data but without sepsis/SS, the start of antibiotic treatment 
can be delayed until microbiological confirmation, without this implying an increase in 
mortality or stay in the ICU.
3. Designate a nurse as a project reference and responsible for the control of precautions 
directed to preventing the transmission of MRB. Ensure the effective implementation of the 
handwashing strategy, and dispose of an alcohol-based preparation dispenser in each bed.
4. Perform an active search for the presence of MRB in all patients at the time of admission to 
the ICU, and at least once a week throughout their stay. The type and number of samples 
will be chosen according to the local epidemiology, and at a minimum, they will include 
Figure 1. Decrease of acquired in ICU infection rate (patients with acquired in ICU infections for every 100 patients 
admitted to the ICU) during the different zero projects. Start of BZ 2009: Start of NZ 2011; start of Resistance Zero 2014.
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nasal, rectal and oropharyngeal swabs (tracheal aspirate in intubated patients); in addi-
tion, you can take other samples to control possible reservoirs (infections, skin ulcers, etc). 
The samples will be processed to identify the MRBs recommended by the local epidemiol-
ogy, according to Microbiology and the infection control teams of each hospital.
5. At the time of admission of each patient in ICU, a checklist that includes several items 
(hospital admission>5 days in the previous 3 months, institutionalized-prison, social 
health centers, nursing homes-, colonized or infected by MRB) will be completed., 
antibiotics> = 7 days in the previous month -especially with third and fourth genera-
tion cephalosoporins, quinolones and carbapenemics-, chronic renal failure undergoing 
hemodialysis or chronic ambulatory peritoneal dialysis, and chronic pathology with a 
high incidence of MRB colonization/infection-cystic fibrosis, bronchiectasis, chronic 
ulcers-) with the objective of identifying those patients with high risk of being carriers 
of MRB. In patients with one or more risk factors, preventive contact precautions will be 
applied, and surveillance culture samples will be collected.
6. Control compliance with the different types of precautions that should be applied: 
standard, or based on transmission mechanisms (isolation). The precautions will vary 
according to the identified MRB and its transmission mechanism (drops, air, and contact). 
They are mandatory standards for all health personnel and for the families of the patient. 
Nursing empowerment must be recognized to control strict compliance. The presence of 
necessary material for its application must also be facilitated. Contact isolation should be 
practiced with the use of a coat and gloves before contacting the patient, and removing 
them before leaving the patient’s environment (for a single use).
7. Have an updated protocol for daily and terminal cleaning of rooms occupied by patients 
with MRB. Several aspects must be agreed with the cleaning and Preventive Medicine 
teams of the hospital: the cleaning method (method, frequency, products, etc.) according 
to the type of surface and the fixed structures present, including the beds.
8. Elaborate a document for cleaning the clinical material and scanning devices in the ICU, 
commonly used in hospitalized patients, assessing whether cleaning, disinfection or 
sterilization is necessary. The importance of cleaning the sanitary material (fondendo-
scopes, fiberoptic bronchoscopes, etc.) and nonsanitary (computer keyboards, landline 
and mobile phones, keys, etc.) usually used in the ICU should be made aware. It is the 
responsibility of each worker to clean and disinfect appliances for personal use.
9. Include products containing chlorhexidine (4% soaps or other products impregnated with 2%) 
in the daily hygiene of patients colonized/infected with MRB, in addition to the obvious 
need for cleaning to eliminate organic waste.
10. Given the suspicion of an epidemic outbreak, it is recommended to typify at a molecular 
level the causative microorganism to know the clone responsible for the outbreak and its 
traceability. Studies of outbreaks based on phenotypic characteristics (antigenic, metabolic 
or antibiotic resistance properties) are insufficient to establish conclusive differences or simi-
larities between microorganisms. The molecular typing allows us to know the transmission 
mechanisms of the pathogen to establish measures that prevent its dissemination. The centers 
that do not have means can submit the microbiological samples to the Resistance Vigilance 
Program of the National Microbiology Center of the Carlos III Health Institute (Madrid).
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As additional recommendations, hand hygiene is very important, with the use of hydroal-
coholic solution by health personnel before and after patient care. It is the most effective 
measure for the transmission of germs. Its purpose is to prevent the transmission of microor-
ganisms in a bidirectional way between professionals and patients, besides protecting the care 
environment of pathogenic microorganisms. The priority method to perform hand hygiene 
in the absence of organic matter or visible dirt is the friction with alcohol-based products. 
They will not be used in case of contact with patients/surfaces contaminated with spores 
(C difficile). Gloves should be worn in several situations: when handling blood or body fluids, 
mucous membranes or non-intact skin, when transporting or touching surfaces stained with 
blood, liquids or body fluids, or performing any procedure of blood extraction or parenteral 
treatment. They must be changed if they are broken or contaminated, between one patient 
and another, and between procedures in the same patient. The misuse of gloves increases the 
risk of pathogen transmission, and its use never substitutes for hand hygiene.
The indicators used in the RZ project are:
• Rates of patients with one or more BMR acquired in ICU: number of patients admitted to the 
ICU with 1 or more MRBs identified after 48 h of admission (and up to 48 h after discharge 
from the ICU) for 1000 days of stay in ICU, or by 100 patients admitted. MRBs are evalu-
ated in clinical samples (infections or colonizations) and in surveillance samples, but not in 
environmental samples.
• Rate of days free of antibiotics: number of days—patient who does not receive systemic 
antibiotics for 1000 days of ICU stay. All systemic antibiotics are included regardless of the 
reason for their use.
• Rate of antibiotic use in infections acquired in ICU: number of days - patient with systemic 
antibiotic treatment for infections acquired in ICU, for 1000 days of ICU stay.
The project is complex and flexible, and adapts to the reality of each hospital. It is also contem-
plated to apply an integral security plan that seeks to promote and strengthen the safety culture 
in the daily work in the ICUs. Health professionals who provide critical care to the critically ill 
patients must be aware of the security risks of our units. The culture in general safety of the unit 
must be evaluated. We must work proactively on the potential risks of critical patient care, and 
propose recommendations based on daily practice that tries to minimize them. The notification 
of errors should be encouraged, and a goal of improvement should be proposed over time, with 
follow-up of proposed measures to achieve it. We have developed daily checklist tools that 
assess the safety of the patient on a daily basis in the different spheres of their management, and 
even a list of daily objectives—need of tubes/catheters, assessing whether parenteral medication 
can be suspended or passed to oral route, possibility of discharge from the ICU, and so on.
This project has preceded and promoted the creation of a new National System for the Sur-
veillance of Infection Related to Health Care in Spain, in agreement with the Ministry of Health.
3. European data. ECDC
Data on infections associated with healthcare acquired in ICU are assessed by the ECDC. 
Recent data (2015) [1, 2] show that 8.3% of patients who remain in the ICU for more than 
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Figure 2. North-south and west-east gradient of % resistance of K. pneumoniae to third generation cephalosporins.
48 h develop at least one infection (pneumonia, bacteremia or urinary tract infection). The 
most frequent causal germs are P. aeruginosa (pneumonia), Staphylococcus spp. coagulase-
negative (bacteremia) and Escherichia coli (urinary tract infections). On average, 23.1% of S. 
aureus are MRSA; 3.4% of Enterococci are VRE. Resistance to third generation penicillin is 
described in variable percentages in E coli (20%), Klebsiella (43%) and Enterobacter (42%); 
resistance to carbapenems is also noticeable in Klebsiella (11%), Pseudomonas aeruginosa (24%) 
and Acinetobacter baumannii (69% of averages). In a report of the European Antimicrobial 
Resistance Surveillance Network (EARS-Net) of 2016 [2], the main surveillance system in the 
European Union on bacteria that can cause serious infections, broad variations are described 
in relation to bacterial species, antimicrobial group and geographical region. For many com-
binations of bacterial species (E. coli, K. pneumoniae, P. aeruginosa, Acinetobacter, S. aureus, 
Enterococcus)—resistance to antimicrobial groups, there is a growing gradient from north 
to south, and from west to east, perhaps in relation to variations in the use of antimicrobi-
als, infection prevention and control practices, and differences in diagnosis and healthcare 
utilization patterns between countries [18]. Overall, there seems to be a slowly increasing 
resistance over time (in the 2013–2016 interval) of E coli resistant to one of the three key anti-
microbial groups (fluoroquinolones, third generation cephalosporins and aminoglycosides), 
with a tendency to stabilize the percentage of K. pneumoniae resistances (Figure 2).
4. Global data in Spain: ENVIN study: RZ project
The national study of nosocomial infection surveillance (ENVIN) represents the effort main-
tained over time (since 1994) to know and reduce the prevalence of nosocomial infection 
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in ICUs. It describes nosocomial infections (NI) acquired in ICUs associated with invasive 
instrumentation. The data are collected mainly during the second quarter of the year (few 
units carry out the project throughout the year). The more frequent NI in the ICU are urinary 
infections associated with urinary catheter (31.87%), followed by ventilation-associated 
pneumonia (29.97%) and bacteremia (catheter-associated bacteriemia in 11.31%). In recent years, 
there has been a relative increase in the former ones and a decrease in the latter. The most 
frequently isolated germs in ICU infections (excluding bacteremia from other foci) are: E. coli 
(14.1%), P. aeruginosa (12.9%), K. pneumoniae (9.8%), S. epidermidis (8.2%), S. aureus (4.9%), C. 
albicans (4.8%), E. cloacae (3.5%), S. marcescens (2.7%), and so on. The type of reported patients 
is variable: medical (44%), 19.5% of surgeries scheduled, 10.3% of urgent surgeries and 19.8% 
of coronary patients. The extrinsic risk factors for nosocomial infections are: antibiotics before 
admission (21.1%), antibiotic treatment in ICU (64%), surgery in 30 days before (32.8%), 
urgent surgery during their stay in ICU (10.2%), central venous catheter (63.9%), mechanical 
ventilation (42.4%), bladder catheter (76.4%), parenteral nutrition (8.3%), and so on.
The implementation of the RZ project is more complex than the previous programs. It involves 
the collaboration of more staff and services, so the number of participating ICUs has been 
lower (of>190 in the first two projects, compared to 103 in RZ). In the following graphs, the 
evolution of the different indicators collected in the project is reviewed.
The evolution by quarters of the frequency of colonization/infection of patients with MRB, per 
100 patients admitted, throughout the development of the RZ project is observed in Figure 3, 
with an ascending tendency with peaks coinciding with the collection periods of data from 
the ENVIN project (second quarter of each year). The average value throughout the project 
is 6.23 patients per 100 admissions. The colonization/infection plot for 1000 stays is similar.
Throughout the RZ project, there is an increase in the isolation of germs at the admission 
(acquisition prior to admission to the ICU) versus isolation during their stay (discrete decrease), 
Figure 3. Temporal variation of the rate of MRB colonization/infection in ICU.
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Figure 4. Evolution of BMR isolates prior to admission to the ICU and during admission.
taking into account colonizations and infections (Figure 4). The average value during the proj-
ect is 3.84 patients% (previous) and 2.60% (during), with an increase of the previous ones of 
26% and a decrease of those acquired during the ICU admission of 16.7%.
In relation to the germs acquired in the ICU, there was a slight increase in colonization (5%) 
and a significant decrease in MRB infections (45%) (Figure 5), with average values of 1.75% 
patients colonized and 1.09% of infected.
Figure 1 (see above) and the following ones (Figures 6–8) show the tendencies initiated with 
the BZ and NZ projects of descent of patients admitted to the ICU with an infection (up to 
8.7%, Figure 1), of reducing the use of antibiotics (up to 19.5% of patients, Figure 6), of reduc-
ing the days of antibiotic treatment (DOT, up to 109.7 per 1000 stays, Figure 7) and increasing 
days without antibiotic treatment (up to 40%, Figure 8). A rate of 2.15 antibiotics per patient 
with antibiotic treatment is described in 2016.
MRB colonization-infection rates change in successive years (Figure 9), with significant increases 
in enterobacteria carrying ESBL and carbapenemases and decrease in A. baumannii, P. aeruginosa 
and MRSA.
We can distinguish between the isolation of germs upon admission and during their stay, 
which can allow us to distinguish the predominant MRB germs that the patient “brings” to 
the ICU with those that he/she “acquires” during his stay. Figure 10 shows that Acinetobacter 
infections appear mostly during their stay, against infections by ESBL-producing germs that 
are mostly present at admission.
Figures 11 and 12 show an important variability in the different autonomous communities, 
both in the MRB isolation rate (global of 6.23 per 100 patients) and in the isolated MRB types, 
for a total of 3195 isolated MRBs.
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Figure 5. Evolution of colonized and infected patients during their stay in the ICU.
Figure 6. Reduction in the use of antibiotics over time.
Figure 7. Reduction in the use of days of antibiotic treatment (DOT) for 100 stays in the recent years.
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Figure 8. Increase in the number of days in the ICU without antibiotic treatment over the years.
Figure 9. Infection/colonization by MRB. ENVIN study in the interval 2006–2016.
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Figure 10. Isolation of MR germs in the RZ period globally, upon admission and during their stay in the ICU.
Figure 11. Isolation rate in the different autonomous communities. AND Andalucia, ARAG Aragón, ASTUR Asturias, 
BALEAR Balearic Islands, CANAR Canary Islands, CAST-L Castilla-León, CAST-M Castilla-La Mancha, CAT Catalonia, 
EXTR Extremadura, RIOJA La RIOJA, GALIC Galicia, MADR Madrid, MURC Murcia,NAV Navarra, VAL Valencian 
community, EUSK Euskadi, C/M Ceuta/Melilla.
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Figure 12. Heterogeneity of MRB isolates, counting colonizations and infections, during the period of RZ study. In 
most autonomous communities, the most frequent type of MRB is ESBL producing GNB. The presence of A. baumannii 
has become much less frequent, except in Extremadura and Asturias. In the Canary Islands, there are 0 VRE isolates; 
in Extremadura, there are zero isolates of VRE, one isolation of carbapenemase producing germ and three isolates of P. 
aeruginosa; there are few isolates of A. baumannii in Aragón [9], Canary Islands [8], Galicia [3] and Navarra [5]; and finally 
there is no isolation (0) of A. baumannii in Euskadi.
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5. Data of the ICU of the hospital of Sagunto
Our unit starts the data collection in the ENVIN project the same year of its beginning (1994). 
We started the RZ project in April 2014, and until now (January 2018) have followed the 
guidelines of the RZ project in the prevention and management of patients with MRB. We 
reported 195 isolates in 179 patients for 46 months, with 1966 admissions and a rate of 9.1 
patients with MRB/100 admissions (Figure 13).
In our unit, a high prevalence of A. baumannii was initially observed, without a clear seasonal 
profile. Over time, there is a decrease in A. baumannii and an increase in the ESBL carrier 
Figure 13. Occurrence of MRB in our ICU Fromm the beginning of RZ project until February 2018. Acinetobacter 
supposes globally a 25% of isolates, with a rate of 50% of ESBL producer germs.
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Figure 16. Indicators of the RZ project at the local (hospital of Sagunto), regional (Valencian community) and national 
(Spain) levels.
Figure 14. Accumulated frequency of colonized and infected patients by A. baumannii and ESBL producer germs.
Figure 15. Accumulated frequency of colonized and infected patients by the most frequently isolated germs in the ICU 
of the hospital of Sagunto.
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bacteria, and a slowly increasing incidence of MRSA and P. aeruginosa (Figure 13). Assessing 
the cumulative incidence, there is a catch-up of the ESBL + germs to the initially predominant 
Acinetobacter at the end of 2015–beginning of 2016 (Figure 14); if we separate the ESBL + 
germs, the highest cumulative frequency of E coli than of A. baumannii is observed at the end 
of 2016. In the last months also, the frequency of occurrence of K. pneumoniae is higher than 
that of A. baumannii (Figure 15).
During the RZ project, in our unit, 80 MRB were detected on admission and 26 during stay; 
this implies a global estimate, during the entire project period, of 6.29 patients with BMR at 
admission for every 100 admitted patients, and 2.04 patients with BMR during their stay in 
ICU per 100 patients admitted and 5.72 patients for 1000 stays. The income indicator is signifi-
cantly higher than that of the Valencian Community (2.22%) and the national one (2.62%); and 
the indicators during their income are only slightly larger than the regional (1.87 and 4.28‰) 
and national (1.82 and 3.36‰) estimates (Figure 16). There have only been three nosocomial 
infections for BMR acquired in ICU during this RZ period, 1 for Pa and 2 for Ab, with a BMR 
infection rate acquired in ICU lower (0.24 per 100 patients admitted to ICU) than the regional 
(0.60%) and the national rates (0.79%).
The profile of germs is different: predominance in our unit of germs producing ESBL + (42.8%) 
and A. baumannii (35.3%), with a lower presence of P. aeruginosa (10.9%) and MRSA (10.1%). 
%); while at the regional and national level, the most common germs in decreasing order are 
Enterobacteria ESBL + (42.6% regional and 42% national), MRSA (21.5 and 21.2%), P. aeruginosa 
(16.7 and 16.8%), A. baumannii (10.5 and 9.2%) and GNB producers of carbapenemases (8.3 
and 9.1%) (Figure 17).
Figure 17. MRB isolated at admission and during their stay, such as colonization or infection, at the local, regional and 
national levels.




The problem of multidrug resistance is serious. The loss of efficacy of antibiotics, within our 
current technified medicine, would limit procedures such as transplants, complex surgeries, 
the management of cancer patients, and so on. It is the responsibility of EVERYBODY to make 
an efficient use of antibiotics. We must remember that a large part of the use of these molecules 
is done at the industrial level, out of sanitary management.
The striking finding of the NORTH-SOUTH and WEST-EAST gradient of MRB isolates fre-
quency can have several explanations: different policies of antibiotic use, environmental condi-
tions (heat) that favors the persistence of certain germs in the hospital environment, variable 
culture of security within the hospital centers, and so on.
The RZ project, despite the difficulties in its development, shows efficacy in reducing MRB 
infections acquired in the ICU. It has been achieved up to 40% of the days in ICU without 
the use of antibiotics. The number of germs discovered at the time of admission is greater 
than during the stay in ICU. The MRBs that caused colonization acquired in ICU increased, 
while the infections acquired by BMR decreased. A great proportion of MRSA and ESBL 
among isolated microorganisms has been documented on admission, and germs producers 
of carbapenemases, P. aeruginosa and A. baumannii are more frequent during their stay in the 
ICU. There are important differences between autonomous communities; there may even 
be differences between different units of critics of the same hospital. The active search for 
MRB in patients at the time of admission has doubled its detection. The application of the 
recommended measures in RZ has achieved to reduce acquired MRB infections acquired 
up to 45%.
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